In recent days, trade and legal journals in the United States have been reporting a figure that makes a broader dynamic immediately clear. When regulation fails to keep pace with scientific evidence, litigation steps in. More than 10,000 lawsuits have now been filed against major manufacturers of chemical hair relaxers by women who link long-term exposure to products containing formaldehyde or formaldehyde-releasing agents to serious illnesses, including uterine and ovarian cancers.
This growing wave of legal action is unfolding against a backdrop of prolonged regulatory delay. Despite the well-established carcinogenic nature of formaldehyde, the U.S. Food and Drug Administration has repeatedly missed its own deadlines to introduce a ban on the substance in hair-straightening products. Regulatory discussions have been ongoing for years, and a proposed rule has existed since 2023, yet concrete protective measures have not followed. In this regulatory vacuum, it is not policy but litigation that is now driving accountability and change.
This sequence is far from unprecedented. Legal history offers multiple examples in which courts have played a decisive role when regulators failed to act in a timely manner despite mounting scientific evidence. The case of asbestos remains one of the most emblematic. For decades, its link to mesothelioma, lung cancer and other severe diseases was known, yet its widespread industrial use continued. It was only after hundreds of thousands of lawsuits and enormous compensation claims that asbestos bans were broadly implemented. Regulation, in this case, followed litigation rather than anticipating it.
A similar trajectory can be observed in the litigation surrounding cosmetic talc. Long before regulators imposed meaningful restrictions, courts across the United States heard claims linking talc-based products to ovarian cancer. More than 40,000 lawsuits were filed, leading to landmark verdicts and settlements amounting to billions of dollars. Ultimately, major manufacturers withdrew talc-based baby powder from the global market not as a result of regulatory intervention, but under sustained legal and public pressure.
The current litigation involving formaldehyde-containing hair products fits squarely within this historical pattern. Its implications also extend well beyond the cosmetics sector. Hospitals and healthcare institutions are not exempt from comparable risks. Formaldehyde and formalin continue to be used in clinical and laboratory environments, despite their classification as hazardous substances. As long as these chemicals remain in use, employers face potential legal exposure from healthcare workers who experience occupational contact.
In this context, the absence of an explicit regulatory ban does not equate to protection. Rather, it shifts responsibility onto institutions that continue to rely on hazardous substances despite the availability of safer alternatives. Regulatory inertia does not eliminate risk. It redistributes it across workplaces, professional roles and legal systems.
Courts have repeatedly demonstrated their willingness to intervene where precautionary principles are disregarded and where the scientific basis for harm is well established. Litigation becomes, in effect, a corrective mechanism when regulatory frameworks prove too slow or too cautious to respond.
The question raised by the current wave of formaldehyde-related lawsuits therefore extends beyond a single substance or industry. It speaks to the broader role of law as a safeguard when regulation lags behind evolving scientific knowledge. Waiting for formal bans may appear administratively prudent, but experience shows that such delays often carry significant legal, ethical and human costs.
When safer alternatives already exist, the issue is no longer whether institutions are compliant with the letter of current regulations. It is whether continuing to wait is worth the risk.